Chagas disease: The challenge of polyparasitism?

Trends in Parasitology

Volumn 30, Issue 4, 2014, Pages 176-182

  Perez, Catherine J ^a   Lymbery, Alan J ^a   Thompson, R C Andrew ^a  

^a MURDOCH UNIVERSITY   (Australia)

Author keywords

Chagas disease; Drug discovery; Polyparasitism; Trypanosoma cruzi

Indexed keywords

CHAGAS DISEASE; GENETIC VARIABILITY; HOST PARASITE INTERACTION; HUMAN; IMMUNE RESPONSE; KINETOPLASTID LIFE CYCLE STAGE; LEISHMANIA; MIXED INFECTION; NONHUMAN; PARASITE TRANSMISSION; PARASITE VIRULENCE; PARASITEMIA; PARASITISM; REVIEW; SENSITIVITY AND SPECIFICITY; TRYPANOSOMA CRUZI; ASYMPTOMATIC INFECTION; CHRONIC DISEASE; CONCURRENT INFECTION; DIAGNOSTIC PROCEDURE; FATALITY; IMMUNE EVASION; INFECTION CONTROL; SUDDEN DEATH;

MASTIGOPHORA (FLAGELLATES); PROTOZOA; TRYPANOSOMA CRUZI;

CHAGAS DISEASE; DRUG DISCOVERY; POLYPARASITISM; TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS DISEASE; COINFECTION; GENETIC VARIATION; HOST-PARASITE INTERACTIONS; HUMANS; TRYPANOSOMA CRUZI;

EID: 84897090520     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2014.01.008     Document Type: Review

References (63)

1. Hotez P.J., et al. Control of neglected tropical diseases. N. Engl. J. Med. 2007, 357:1018-1027.
2. Hotez P.J., et al. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl. Trop. Dis. 2008, 2:e300.
3. Montilla M., et al. Infestation by triatomine bugs in indigenous communities of Valledupar, Colombia. Rev. Saude Publica 2011, 45:773-780.
4. Hotez P.J., et al. Chagas disease: "the new HIV/AIDS of the Americas". PLoS Negl. Trop. Dis. 2012, 6:e1498.
5. Barrett M.P., Croft S.L. Management of trypanosomiasis and leishmaniasis. Br. Med. Bull. 2012, 104:175-196.
6. WHO Expert Committee Control of Chagas disease. World Health Organ. Tech. Rep. Ser. 2002, 905:i-vi. 1-109, back cover.
7. Zingales B., et al. The revised Trypanosoma cruzi subspecific nomenclature: rationale, epidemiological relevance and research applications. Infect. Genet. Evol. 2012, 12:240-253.
8. Henao-Martinez A.F., et al. Chagasic cardiomyopathy, from acute to chronic: is this mediated by host susceptibility factors?. Trans. R. Soc. Trop. Med. Hyg. 2012, 106:521-527.
9. Teixeira A.R., et al. Evolution and pathology in Chagas disease - a review. Mem. Inst. Oswaldo Cruz 2006, 101:463-491.
10. Gascon J., et al. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 2010, 115:22-27.
11. Schmunis G.A., Yadon Z.E. Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop. 2010, 115:14-21.
12. Llewellyn M.S., et al. Extraordinary Trypanosoma cruzi diversity within single mammalian reservoir hosts implies a mechanism of diversifying selection. Int. J. Parasitol. 2011, 41:609-614.
13. Morocoima A., et al. Trypanosoma cruzi: experimental parasitism in the central nervous system of albino mice. Parasitol. Res. 2012, 111:2099-2107.
14. Caballero Z.C., et al. Evaluation of serological tests to identify Trypanosoma cruzi infection in humans and determine cross-reactivity with Trypanosoma rangeli and Leishmania spp. Clin. Vaccine Immunol. 2007, 14:1045-1049.
15. Sanchez Negrette O., et al. Serological evaluation of specific-antibody levels in patients treated for chronic Chagas disease. Clin. Vaccine Immunol. 2008, 15:297-302.
16. Ramirez J.D., et al. Evaluation of adult chronic Chagas heart disease diagnosis by molecular and serological methods. J. Clin. Microbiol. 2009, 47:3945-3951.
17. De Winne K., et al. The Trypanosoma cruzi satellite DNA oligoC-test and Trypanosoma cruzi kinetoplast DNA oligoC-test for diagnosis of Chagas disease: a multi-cohort comparative evaluation study. PLoS Negl. Trop. Dis. 2014, 8:e2633.
18. Kierszenbaum F. Chagas disease and the autoimmunity hypothesis. Clin. Microbiol. Rev. 1999, 12:210-223.
19. Tarleton R.L., et al. The challenges of Chagas disease - grim outlook or glimmer of hope. PLoS Med. 2007, 4:e332.
20. Frank F.M., et al. Characterization of human infection by Leishmania spp. in the Northwest of Argentina: immune response, double infection with Trypanosoma cruzi and species of Leishmania involved. Parasitology 2003, 126:31-39.
21. Pereira Gde A., et al. Performance of six diagnostic tests to screen for Chagas disease in blood banks and prevalence of Trypanosoma cruzi infection among donors with inconclusive serology screening based on the analysis of epidemiological variables. Rev. Bras. Hematol. Hemoter. 2012, 34:292-297.
22. Vago A.R., et al. Genetic characterization of Trypanosoma cruzi directly from tissues of patients with chronic Chagas disease: differential distribution of genetic types into diverse organs. Am. J. Pathol. 2000, 156:1805-1809.
23. Antoniou M., et al. Short report: Treatment failure due to mixed infection by different strains of the parasite Leishmania infantum. Am. J. Trop. Med. Hyg. 2004, 71:71-72.
24. Manning L., et al. A histopathologic study of fatal paediatric cerebral malaria caused by mixed Plasmodium falciparum/Plasmodium vivax infections. Malar. J. 2012, 11:107.
25. Andersson J., et al. Chronic murine Chagas disease: the impact of host and parasite genotypes. Immunol. Lett. 2003, 86:207-212.
26. Macedo A.M., Pena S.D. Genetic variability of Trypanosoma cruzi: implications for the pathogenesis of Chagas disease. Parasitol. Today 1998, 14:119-124.
27. Roellig D.M., et al. Genetic variation and exchange in Trypanosoma cruzi isolates from the United States. PLoS ONE 2013, 8:e56198.
28. Dias G.B., et al. Evolution of infection in mice inoculated by the oral route with different developmental forms of Trypanosoma cruzi I and II. Exp. Parasitol. 2013, 135:511-517.
29. Yoshida N. Trypanosoma cruzi infection by oral route: how the interplay between parasite and host components modulates infectivity. Parasitol. Int. 2008, 57:105-109.
30. Miles M.A. Orally acquired Chagas disease: lessons from an urban school outbreak. J. Infect. Dis. 2010, 201:1282-1284.
31. Cortez M., et al. Trypanosoma cruzi surface molecule gp90 downregulates invasion of gastric mucosal epithelium in orally infected mice. Microbes Infect. 2006, 8:36-44.
32. Coura J.R., et al. Emerging Chagas disease in Amazonian Brazil. Trends Parasitol. 2002, 18:171-176.
33. Segovia M., et al. Molecular epidemiologic source tracking of orally transmitted Chagas disease, Venezuela. Emerg. Infect. Dis. 2013, 19:1098-1101.
34. Toledo M.J., et al. Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes. Antimicrob. Agents Chemother. 2003, 47:223-230.
35. Teston A.P., et al. In vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the western Brazilian Amazon. Trop. Med. Int. Health 2013, 18:85-95.
36. Fernandes M.C., Andrews N.W. Host cell invasion by Trypanosoma cruzi: a unique strategy that promotes persistence. FEMS Microbiol. Rev. 2012, 36:734-747.
37. Viotti R., et al. Towards a paradigm shift in the treatment of chronic Chagas disease. Antimicrob. Agents Chemother. 2014, 58:635-639.
38. Marin-Neto J.A., et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am. Heart J. 2008, 156:37-43.
39. Alviano D.S., et al. Conventional therapy and promising plant-derived compounds against trypanosomatid parasites. Front. Microbiol. 2012, 3:283.
40. Andriani G., et al. Activity in vivo of anti-Trypanosoma cruzi compounds selected from a high throughput screening. PLoS Negl. Trop. Dis. 2011, 5:e1298.
41. Rozas M., et al. Coexistence of Trypanosoma cruzi genotypes in wild and periodomestic mammals in Chile. Am. J. Trop. Med. Hyg. 2007, 77:647-653.
42. Diez C., et al. Genotyping of Trypanosoma cruzi sublineage in human samples from a North-East Argentina area by hybridization with DNA probes and specific polymerase chain reaction (PCR). Am. J. Trop. Med. Hyg. 2010, 82:67-73.
43. Lainson R., Shaw J.J. Epidemiology and ecology of leishmaniasis in Latin-America. Nature 1978, 273:595-600.
44. Araujo C.A., et al. Growth behaviour of two Trypanosoma cruzi strains in single and mixed infections: in vitro and in the intestinal tract of the blood-sucking bug, Triatoma brasiliensis. Acta Trop. 2007, 101:225-231.
45. Martins H.R., et al. Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi. Antimicrob. Agents Chemother. 2007, 51:3282-3289.
46. Lymbery A.J., Thompson R.C. The molecular epidemiology of parasite infections: tools and applications. Mol. Biochem. Parasitol. 2012, 181:102-116.
47. Pullan R., Brooker S. The health impact of polyparasitism in humans: are we under-estimating the burden of parasitic diseases?. Parasitology 2008, 135:783-794.
48. Petney T.N., Andrews R.H. Multiparasite communities in animals and humans: frequency, structure and pathogenic significance. Int. J. Parasitol. 1998, 28:377-393.
49. Rodrigues C.M., et al. Coinfection with different Trypanosoma cruzi strains interferes with the host immune response to infection. PLoS Negl. Trop. Dis. 2010, 4:e846.
50. Salcedo-Cifuentes M., et al. Intestinal parasitism prevalence amongst children from six indigenous communities residing in Cali, Colombia. Rev. Salud Publica (Bogota) 2012, 14:156-168.
51. Galán-Puchades M., Osuna A. Chagas disease in a wormy world. Rev. Ibero-Latinoam. Parasitol. 2012, 71:5-13.
52. Rodrigues M.M., et al. Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene. Infect. Immun. 1999, 67:3855-3863.
53. Tarleton R.L., et al. Increased susceptibility of Stat4-deficient and enhanced resistance in Stat6-deficient mice to infection with Trypanosoma cruzi. J. Immunol. 2000, 165:1520-1525.
54. + Th1 cells in systemic immunity protective against primary and secondary challenges with Trypanosoma cruzi. Infect. Immun. 2000, 68:197-204.
55. Sartori A.M., et al. Trypanosoma cruzi parasitemia in chronic Chagas disease: comparison between human immunodeficiency virus (HIV)-positive and HIV-negative patients. J. Infect. Dis. 2002, 186:872-875.
56. Perez-Molina J.A., et al. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment. Acta Trop. 2013, 127:101-104.
57. de Roode J.C., et al. Virulence and competitive ability in genetically diverse malaria infections. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:7624-7628.
58. Taylor L.H., et al. Virulence of mixed-clone and single-clone infections of the rodent malaria Plasmodium chabaudi. Evolution 1998, 52:583-591.
59. Brener Z. Biology of Trypanosoma cruzi. Annu. Rev. Microbiol. 1973, 27:347-382.
60. Peacock C.S., et al. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nat. Genet. 2007, 39:839-847.
61. Botero A., et al. Trypanosomes genetic diversity, polyparasitism and the population decline of the critically endangered Australian marsupial, the brush tailed bettong or woylie (Bettongia penicillata). Int. J. Parasitol. Parasit. Wildl. 2013, 2:77-89.
62. Oliveira L.R.C., et al. Organ tropism during the acute and chronic phases of Trypanosoma cruzi infection in BALB/c mice. J. Venom. Anim. Toxins incl. Trop. Dis. 2012, 18:34-43.
63. Andrade L.O., et al. Trypanosoma cruzi: role of host genetic background in the differential tissue distribution of parasite clonal populations. Exp. Parasitol. 2002, 100:269-275.